Literature DB >> 24888802

Past, present, and future challenges in breast cancer treatment.

George W Sledge1, Eleftherios P Mamounas2, Gabriel N Hortobagyi3, Harold J Burstein4, Pamela J Goodwin5, Antonio C Wolff6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24888802      PMCID： PMC4879690          DOI： 10.1200/JCO.2014.55.4139

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  91 in total

1.  High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Authors:  Ana M Gonzalez-Angulo; Jennifer K Litton; Kristine R Broglio; Funda Meric-Bernstam; Ronjay Rakkhit; Fatima Cardoso; Florentia Peintinger; Emer O Hanrahan; Aysegul Sahin; Merih Guray; Denis Larsimont; Francesco Feoli; Heidi Stranzl; Thomas A Buchholz; Vicente Valero; Richard Theriault; Martine Piccart-Gebhart; Peter M Ravdin; Donald A Berry; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

2.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

3.  High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

Authors:  Donald A Berry; Naoto T Ueno; Marcella M Johnson; Xiudong Lei; Jean Caputo; Sjoerd Rodenhuis; William P Peters; Robert C Leonard; William E Barlow; Martin S Tallman; Jonas Bergh; Ulrike A Nitz; Alessandro M Gianni; Russell L Basser; Axel R Zander; R Charles Coombes; Henri Roché; Yutaka Tokuda; Elisabeth G E de Vries; Gabriel N Hortobagyi; John P Crown; Paolo Pedrazzoli; Marco Bregni; Taner Demirer
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

4.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Authors:  Trevor J Powles; Sue Ashley; Alwynne Tidy; Ian E Smith; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

Review 5.  Effect of obesity on breast cancer development.

Authors:  M P Cleary; M E Grossmann; A Ray
Journal:  Vet Pathol       Date:  2010-02-01       Impact factor: 2.221

6.  Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  Luca Gianni; Anna Lladó; Giulia Bianchi; Javier Cortes; Pirkko-Liisa Kellokumpu-Lehtinen; David A Cameron; David Miles; Stefania Salvagni; Andrew Wardley; Jean-Charles Goeminne; Veronica Hersberger; José Baselga
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

7.  Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ.

Authors:  Todd M Tuttle; Stephanie Jarosek; Elizabeth B Habermann; Amanda Arrington; Anasooya Abraham; Todd J Morris; Beth A Virnig
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

8.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Authors:  H B Muss; A D Thor; D A Berry; T Kute; E T Liu; F Koerner; C T Cirrincione; D R Budman; W C Wood; M Barcos
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

Review 9.  Vinorelbine--a clinical review.

Authors:  R K Gregory; I E Smith
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

10.  Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis.

Authors:  Miao Liu; Qin-Guo Mo; Chang-Yuan Wei; Qing-Hong Qin; Zhen Huang; Jie He
Journal:  Oncol Lett       Date:  2012-12-28       Impact factor: 2.967
View more
  66 in total

1.  Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy.

Authors:  J M Cochran; S H Chung; A Leproux; W B Baker; D R Busch; A M DeMichele; J Tchou; B J Tromberg; A G Yodh
Journal:  Phys Med Biol       Date:  2017-04-12       Impact factor: 3.609

2.  Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.

Authors:  Alessandra Decio; Marta Cesca; Francesca Bizzaro; Luca Porcu; Rossana Bettolini; Paolo Ubezio; Giulia Taraboletti; Dorina Belotti; Raffaella Giavazzi
Journal:  Clin Exp Metastasis       Date:  2015-07-17       Impact factor: 5.150

3.  The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model.

Authors:  Jeanette Birnbaum; Vijayakrishna K Gadi; Elan Markowitz; Ruth Etzioni
Journal:  Ann Intern Med       Date:  2016-01-12       Impact factor: 25.391

4.  Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.

Authors:  Erik Hedrick; Xi Li; Yating Cheng; Alexandra Lacey; Kumaravel Mohankumar; Mahsa Zarei; Stephen Safe
Journal:  Breast Cancer Res Treat       Date:  2019-05-22       Impact factor: 4.872

5.  Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast.

Authors:  Yasuaki Sagara; William T Barry; Melissa Anne Mallory; Ines Vaz-Luis; Fatih Aydogan; Jane E Brock; Eric P Winer; Mehra Golshan; Otto Metzger-Filho
Journal:  Ann Surg Oncol       Date:  2015-04-18       Impact factor: 5.344

Review 6.  The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.

Authors:  V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2014-10-22       Impact factor: 5.678

7.  Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.

Authors:  Aparna Maiti; Kazuaki Takabe; Nitai C Hait
Journal:  Cell Signal       Date:  2017-01-17       Impact factor: 4.315

8.  Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Authors:  Aditya Bardia; Ingrid A Mayer; Jennifer R Diamond; Rebecca L Moroose; Steven J Isakoff; Alexander N Starodub; Nikita C Shah; Joyce O'Shaughnessy; Kevin Kalinsky; Michael Guarino; Vandana Abramson; Dejan Juric; Sara M Tolaney; Jordan Berlin; Wells A Messersmith; Allyson J Ocean; William A Wegener; Pius Maliakal; Robert M Sharkey; Serengulam V Govindan; David M Goldenberg; Linda T Vahdat
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

9.  Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.

Authors:  Bruce J Tromberg; Zheng Zhang; Anaïs Leproux; Thomas D O'Sullivan; Albert E Cerussi; Philip M Carpenter; Rita S Mehta; Darren Roblyer; Wei Yang; Keith D Paulsen; Brian W Pogue; Shudong Jiang; Peter A Kaufman; Arjun G Yodh; So Hyun Chung; Mitchell Schnall; Bradley S Snyder; Nola Hylton; David A Boas; Stefan A Carp; Steven J Isakoff; David Mankoff
Journal:  Cancer Res       Date:  2016-08-15       Impact factor: 12.701

10.  Modeling estrogen receptor-positive breast cancers in mice: is it the best we can do?

Authors:  Ioulia Chatzistamou; Hippokratis Kiaris
Journal:  Endocr Relat Cancer       Date:  2016-09-12       Impact factor: 5.678
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.